神經系統

互動

儘管ABEM（Associação Brasileira de Esclerose Múltipla，巴西多發性硬化症協會）並不直接參與藥品定價決策——在巴西，此類決策由CMED（Câmara de Regulação do Mercado de Medicamentos，藥品市場監管委員會）負責——但該組織積極參與有關治療可及性、可用性及永續性的公共與機構辯論，代表多發性硬化症患者及其……

互動

閱讀原始引言

南非多發性硬化症協會（MSSA）代表患者利益，倡導獲得可負擔且有效的多發性硬化症治療方案，並在政策、可及性及報銷討論中傳達患者的聲音。雖然MSSA不制定或協商藥品價格，但我們與監管機構、政策制定者及諮詢機構合作，強調定價與可及性決策對多發性硬化症患者的實際影響，尤其是在南非及更廣泛的非洲背景下。

Multiple Sclerosis South Africa (MSSA) represents patient interests by advocating for access to affordable, effective MS treatments and by contributing the patient voice to policy, access, and reimbursement discussions. While MSSA does not set or negotiate drug prices, we engage with regulators, policymakers, and advisory bodies to highlight the real-world impact of pricing and access decisions on people living with MS, particularly in a South African and broader African context. Our input is informed by lived experience, patient-reported challenges, and international collaboration through global MS networks, ensuring that patient needs, equity, and sustainability are considered in decision-making processes.

行動與倡議

閱讀原始引言

當出現 ASM（抗癲癇藥物）短缺時，我們會凝聚社群力量，並支持為癲癇患者制定藥物價格管制措施。

We rally our community when there are ASM shortages and to support price regulations for medication for patients with epilepsy.

行動與倡議

閱讀原始引言

在智利，多發性硬化症（MS）[Esclerosis Múltiple – Multiple Sclerosis] 的藥物透過 GES [Garantías Explícitas en Salud – 明確健康保障計畫] 發放，該計畫規定了福利套餐的價值。

En Chile, los medicamentos de la EM se entregan a través del GES, el cual define un valor de las canastas.